SBIR-STTR Award

Innovative Green Technology for Advanced, Patient-Centered Home Hemodialysis
Award last edited on: 12/28/2023

Sponsored Program
SBIR
Awarding Agency
NSF
Total Award Amount
$765,957
Award Phase
2
Solicitation Topic Code
BC
Principal Investigator
Takuji Tsukamoto

Company Information

Chemica Technologies Inc (AKA: Chemica Technologies LLC)

2611 Sw Third Avenue Suite 250
Portland, OR 97201
   (503) 352-0262
   webcontact@chemica.com
   www.chemica.com
Location: Single
Congr. District: 03
County: Multnomah

Phase I

Contract Number: 1013344
Start Date: 7/1/2010    Completed: 6/30/2011
Phase I year
2010
Phase I Amount
$175,000
This Small Business Innovation Research (SBIR) Phase I project proposes to develop a mobile, easy-to-use, patient oriented, advanced Home Hemodialysis (HD) system that minimizes the use of water and medical wastes, and importantly, minimizes loss of nutrients. End-stage renal disease (ESRD) is a devastating and disabling disease requiring chronic dialysis treatment, which severely limits the mobility and quality of life (QOL) of ESRD patients and their caregivers due to the time and effort required to receive treatment. At dialysis centers, standard hemodialysis treatment, which utilizes massive amounts of highly purified water, results in a significant loss of nutrients. The objectives of this Phase I project are to design and test key units of an HD machine (HDM), to test the efficacy and safety of the system in vitro and to design a light weight (~22 kg) prototype home HD system equipped with high precision components for in vivo studies. Using minimum dialysate (<6L), the developed home HD system will achieve adequate toxin clearance with minimal ion and serum albumin loss, greatly improving the QOL of ESRD patients and their families by allowing for effective and comfortable treatment at home, work, or school or during travel. The broader impact/commercial potential of this project includes reducing the economic burden of end-stage renal disease (ESRD) on patients and Federal healthcare programs. As the number of ESRD patients approaches 3 million globally, it is becoming critical to decrease the cost and resource burden of the chronic dialysis treatment of these patients by drastically decreasing facility costs, use of water and energy in treatment, and to increase patients' quality of life by facilitating greater flexibility in length and place of treatment. The proposed semi-portable hemodialysis machine offers many advantages over currently available dialysis systems. The advantages are based on both the highly efficient dialysis regeneration capability and the light-weight, precisely configured and controlled machine. The savings in raw water costs alone from use of this HD system would be significant. The savings could be even greater in other parts of the world where water costs are significantly higher (i.e. Germany, Great Britain, etc.) and where access to clean water is becoming increasingly difficult (i.e. China, India, Mexico, etc.). The system will enhance the scientific and technical knowledge in the fields of dialysis and sorbent technologies

Phase II

Contract Number: 1152661
Start Date: 4/15/2012    Completed: 3/31/2015
Phase II year
2012
(last award dollars: 2013)
Phase II Amount
$590,957

This Small Business Innovation Research (SBIR) Phase II project focuses on the further development of an advanced, mobile, easy-to-use, patient-oriented, advanced Home Hemodialysis (HHD) system that minimizes the use of water (less than 6 liters) and medical waste, and importantly, minimizes nutrient loss. End-stage renal disease (ESRD) is a devastating, disabling disease. Many ESRD patients and their family members are severely limited in the mobility and freedom due to the time and effort of having hemodialysis (HD) treatments at hospitals and dialysis centers. Our ultimate goal is to develop a next generation lightweight HD machine (~22 kg) equipped with high precision components and an innovative dialysate regeneration cartridge (DRC). This Phase II program focuses on the construction of a prototype HHD machine that is fully equipped with necessary functions and safety devices. The intellectual merits are based on both the highly efficient and selective DRC composed of a specifically functionalized sorbent, and the compact and highly efficient HD machine that allows for a well-configured and accurately controlled dialysis treatment. This development would greatly improve quality of life for ESRD patients and their families by allowing for effective and comfortable treatment at home, or even at work or school. The broader impact/commercial potential of this project, if successful, is to reduce the economic burden of ESRD on both patients and Federal healthcare programs. As the number of HD patients approaches 3 million globally, it is becoming critical to decrease the cost and resource burden of treating these patients by drastically decreasing facility costs, use of water and energy in treatment. The second impact is to increase patients' quality of life by facilitating greater flexibility in the length and place of treatment (home, school, work). This system also allows for the personalized dialysis treatment of patients through selective adsorption of toxins. The proposed mobile, semi-portable HD machine offers many advantages over currently available dialysis systems, resulting in high commercial potential. The system will enhance the scientific and technical knowledge in the fields of bioengineering of dialysis and chemistry of sorbent technologies. Given the flexibility in dialysis treatment, the quality of life of dialysis patients will be greatly enhanced. Since this product achieves two goals simultaneously, namely improved treatment and reduced cost, it has a significant advantage over many of the competitive products available today.